Artikel: Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis.
2023 Band 14, Seite(n) 1026168
Abstract: Objective: Bromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown. The purpose of this study was ... ...
Abstract | Objective: Bromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown. The purpose of this study was to explore the effect of bromocriptine on the proliferation and migration properties of the endometrium in women with adenomyosis, by assessing cellular and molecular changes after six months of vaginal bromocriptine treatment. Methods: Endometrial specimens were collected during the proliferative phase from women with adenomyosis (n=6) before (baseline) and after six months of treatment with vaginal bromocriptine. Immunohistochemistry was used to determine changes in the protein expression of Ki67 in the endometrium of women with adenomyosis. Primary endometrial stromal cells isolated at baseline were expanded Results: Vaginal bromocriptine treatment reduced the Ki67 protein expression in the endometrium of women with adenomyosis and did not change the prolactin mRNA expression and protein concentration of prolactin in endometrial tissues. Bromocriptine significantly inhibited the proliferative and migrative abilities of endometrial stromal cells derived from women with adenomyosis Conclusion: Bromocriptine treatment exhibits an anti-proliferative effect in the endometrium of women with adenomyosis |
---|---|
Mesh-Begriff(e) | Humans ; Female ; Adenomyosis/drug therapy ; Bromocriptine/pharmacology ; Bromocriptine/therapeutic use ; Ki-67 Antigen/metabolism ; Prolactin/metabolism ; Endometrium/metabolism ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Cell Proliferation |
Chemische Substanzen | Bromocriptine (3A64E3G5ZO) ; Ki-67 Antigen ; Prolactin (9002-62-4) ; MicroRNAs |
Sprache | Englisch |
Erscheinungsdatum | 2023-03-09 |
Erscheinungsland | Switzerland |
Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2592084-4 |
ISSN | 1664-2392 |
ISSN | 1664-2392 |
DOI | 10.3389/fendo.2023.1026168 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.